-
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
•
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total…
-
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company reported revenues of RMB 44 million and a loss of RMB 312 million in 2022, primarily generated through a licensing agreement with Livzon Pharma. In the first…
-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
